Revance Therapeutics, Inc.

Passed

Class Action Period:
November 25, 2019 - October 11, 2021

Lead Plaintiff Deadline:
February 08, 2022

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

(i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until February 08, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.